LYEL

13.8001.62%
LS

Lynn Seely

Principal Executive Officer, President, CEO & Director

Dr. Lynn Seely, MD, Ph.D., serves as an Independent Director at AbCellera Biologics Inc. since June 30, 2026. She served as Lead Independent Director at Blueprint Medicines Corporation since June 2021 until July 18, 2025. She serves as President and Chief Executive Officer at Lyell Immunopharma, Inc. since December 15, 2022 and has been its Director since May 2021 and was its Interim Principal Financial Officer from October 31, 2025 until March 2026 and serves as Principal Executive Officer. She served as Director at TORL BioTherapeutics LLC from 2023 to 2025. She served as Principal Executive Officer and Director at Myovant Sciences Ltd. since June 2016 until January 3, 2021. Dr. Seely had been the President of Myovant Sciences, Inc. since May 2016 until February 2020. She served as the Chief Medical Officer of Medivation, Inc. (formerly Orion Acquisition Corp. II) from March 2005 to October 15, 2015 and served as its Consultant from October 15, 2015 to April 15, 2016. Dr. Seely was responsible for the strategy and execution of Orion Acquisition Corp. II's clinical development programs and for assisting in the evaluation of new opportunities to expand. She has cross-functional expertise within the healthcare industry, including experience in clinical and product development, business development and regulatory affairs. Dr. Seely served as a Vice President of Clinical Development at Anesiva, Inc. (formerly, Corgentech Inc.), from September 2002 to 2005. At Corgentech, Dr. Seely was responsible for all aspects of a large Phase III cardiovascular trial of an E2F decoy and for the strategy and development of a second clinical program for another new chemical entity. Dr. Seely served as a Vice President of Clinical Development at Cytyc Health Corporation and ProDuct Health, Inc. from 2000 to 2001 and was responsible for clinical trial strategy and execution and physician training during commercialization of a novel breast cancer device. Dr. Seely served as a Vice President of Clinical Development for Cytyc Health Corporation's subsidiary of Cytyc Corporation from 2001 to 2002, where she assisted with transitional matters related to Cytyc Corporations acquisition of ProDuct Health, Inc. She completed her residency and served as chief resident in internal medicine at Yale-New Haven Hospital. Dr. Seely served as an Associate Director of Clinical Development at Chiron Corporation since 1996 until 2000, a biotechnology company where she served in clinical development at Chiron Corporation and worked on a broad range of development programs in multiple different therapeutic areas. From July 1992 to November 1996, Dr. Seely served as an Assistant Professor of Medicine at the University of California, San Diego, where she ran a National Institute of Health-funded growth factor signal transduction laboratory and was co-director of the fellowship training program in Endocrinology and Metabolism. She was an Independent Director of Blueprint Medicines Corporation since April 15, 2016 until July 18, 2025. After serving as Chief Resident in Medicine at Yale, she completed a post-doctoral fellowship in Endocrinology and Metabolism at the University of California, San Diego. Dr. Seely holds a B.A. in Journalism from the University of Oklahoma. Dr. Seely holds a Medical Degree from the University of Oklahoma College of Medicine and completed her residency in Internal Medicine at the Yale-New Haven Hospital in New Haven, Conn.

Positions